Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 52(1): 365-73, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17938185

RESUMO

Against 447 anaerobe strains, the investigational carbapenem doripenem had an MIC 50 of 0.125 microg/ml and an MIC 90 of 1 microg/ml. Results were similar to those for imipenem, meropenem, and ertapenem. Time-kill studies showed that doripenem had very good bactericidal activity compared to other carbapenems, with 99.9% killing of 11 strains at 2x MIC after 48 h.


Assuntos
Antibacterianos/farmacologia , Bactérias Anaeróbias/efeitos dos fármacos , Bactérias Anaeróbias/crescimento & desenvolvimento , Carbapenêmicos/farmacologia , Bactérias Anaeróbias/classificação , Contagem de Colônia Microbiana , Doripenem , Humanos , Testes de Sensibilidade Microbiana/normas
2.
Antimicrob Agents Chemother ; 51(2): 770-3, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17116666

RESUMO

LBM415 is a peptide deformylase inhibitor active against gram-positive bacterial species and some gram-negative species. In multiselection studies, LBM415 had low MICs against all Streptococcus pneumoniae strains tested, regardless of their genotype, and selected resistant clones after 14 to 50 days. MIC increases correlated with changes mostly in the 70GXGXAAXQ77 motif in peptide deformylase. The postantibiotic effect of LBM415 ranged from 0.3 to 1.4 h.


Assuntos
Farmacorresistência Bacteriana , Peptídeos/farmacologia , Streptococcus pneumoniae/efeitos dos fármacos , Amidoidrolases/genética , Farmacorresistência Bacteriana/genética , Testes de Sensibilidade Microbiana , Peptídeos/genética , Infecções Pneumocócicas/tratamento farmacológico , Especificidade da Espécie , Streptococcus pneumoniae/genética , Fatores de Tempo
3.
Antimicrob Agents Chemother ; 48(11): 4103-12, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15504828

RESUMO

The MICs of GW 773546, GW 708408, and telithromycin for 164 macrolide-susceptible and 161 macrolide-resistant pneumococci were low. The MICs of GW 773546, GW 708408, and telithromycin for macrolide-resistant strains were similar, irrespective of the resistance genotypes of the strains. Clindamycin was active against all macrolide-resistant strains except those with erm(B) and one strain with a 23S rRNA mutation. GW 773546, GW 708408, and telithromycin at two times their MICs were bactericidal after 24 h for 7 to 8 of 12 strains. Serial passages of 12 strains in the presence of sub-MICs yielded 54 mutants, 29 of which had changes in the L4 or L22 protein or the 23S rRNA sequence. Among the macrolide-susceptible strains, resistant mutants developed most rapidly after passage in the presence of clindamycin, GW 773546, erythromycin, azithromycin, and clarithromycin and slowest after passage in the presence of GW 708408 and telithromycin. Selection of strains for which MICs were >/=0.5 microg/ml from susceptible parents occurred only with erythromycin, azithromycin, clarithromycin, and clindamycin; 36 resistant clones from susceptible parent strains had changes in the sequences of the L4 or L22 protein or 23S rRNA. No mef(E) strains yielded resistant clones after passage in the presence of erythromycin and azithromycin. Selection with GW 773546, GW 708408, telithromycin, and clindamycin in two mef(E) strains did not raise the erythromycin, azithromycin, and clarithromycin MICs more than twofold. There were no change in the ribosomal protein (L4 or L22) or 23S rRNA sequences for 15 of 18 mutants selected for macrolide resistance; 3 mutants had changes in the L22-protein sequence. GW 773546, GW 708408, and telithromycin selected clones for which MICs were 0.03 to >2.0 microg/ml. Single-step studies showed mutation frequencies <5.0 x 10(-10) to 3.5 x 10(-7) for GW 773546, GW 708408, and telithromycin for macrolide-susceptible strains and 1.1 x 10(-7) to >4.3 x 10(-3) for resistant strains. The postantibiotic effects of GW 773546, GW 708408, and telithromycin were 2.4 to 9.8 h.


Assuntos
Antibacterianos/farmacologia , Macrolídeos/farmacologia , Streptococcus pneumoniae/efeitos dos fármacos , Azitromicina/farmacologia , Claritromicina/farmacologia , Clindamicina/farmacologia , Farmacorresistência Bacteriana , Eritromicina/farmacologia , Genes Bacterianos , Cetolídeos/farmacologia , Testes de Sensibilidade Microbiana , Mutação/genética , Streptococcus pneumoniae/genética , Fatores de Tempo
4.
Antimicrob Agents Chemother ; 48(11): 4430-4, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15504874

RESUMO

Agar dilution MIC was used to compare activities of OPT-80, linezolid, vancomycin, teicoplanin, quinupristin/dalfopristin, amoxicillin/clavulanate, imipenem, clindamycin, and metronidazole against 350 gram-positive and -negative anaerobes. OPT-80 was active against gram-positive strains only, especially Clostridium spp. (85 strains tested, including 21 strains of C. difficile), with MICs ranging between

Assuntos
Antibacterianos/farmacologia , Bactérias Anaeróbias/efeitos dos fármacos , Glicosídeos/farmacologia , Clostridium/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Testes de Sensibilidade Microbiana
6.
Antimicrob Agents Chemother ; 47(4): 1399-402, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12654677

RESUMO

The activities of garenoxacin, ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, amoxicillin-clavulanate, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 20 anaerobes were tested. At two times the MIC, garenoxacin was bactericidal against 19 of 20 strains after 48 h and against 17 of 20 after 24 h. Other drugs, except clindamycin (which gave lower killing rates), gave killing rates similar to those for garenoxacin.


Assuntos
Antibacterianos/farmacologia , Bactérias Anaeróbias/efeitos dos fármacos , Fluoroquinolonas , Indóis/farmacologia , Quinolonas/farmacologia , Humanos , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...